TORONTO – Ontario and British Columbia med-tech companies have received CA$1.4 million (US$1 million) from Ottawa’s Supercluster fund, making a difference they said for patients suffering the long-range effects of COVID-19, chronic disease and undergoing joint replacement surgery.
With the FDA perhaps days away from granting emergency use authorization (EUA) for the first U.S. COVID-19 vaccine, the Trump administration took a bow Dec. 8 at a summit called to celebrate what’s been accomplished and to explain what lies ahead in getting vaccines distributed throughout the country.
While med-tech deal values fall significantly short of last year, the 1,240 deals worth $4 billion recorded through November place 2020 above 2018 in terms of value and well above each of the last two years in terms of volume.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Advaite, Airehealth, Rheonix.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acutus Medical, Biotronik, Canary Health Technologies, DDF, Durect, Eurofins, Evonik, Seaspine, Sherlock Biosciences, Smartshape Design.
Harvard University’s Wyss Institute for Biologically Inspired Engineering licensed its Erapid electrochemical sensing platform to IQ Group Global to integrate with the Australian consortium’s transistor technology in a SARS-CoV-2 test. The combined solution could greatly simplify serological testing for the virus and help monitor immunity in individuals and populations over time.
RSS
